Status:
RECRUITING
A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Borrelia Infections
Eligibility:
All Genders
1+ years
Brief Summary
Clinical, biological, radiological, and pharmacological description of cases of disseminated borreliosis (Borrelia burgdorferi sl. and Borrelia miyamotoi) occurring in patients who received drug treat...
Eligibility Criteria
Inclusion Criteria:
- Minor or adult subject
- Having presented disseminated borreliosis confirmed by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.
Exclusion Criteria:
- Refusal to participate in the study
Key Trial Info
Start Date :
August 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 29 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07343089
Start Date
August 29 2025
End Date
August 29 2026
Last Update
January 15 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laboratoire de Bactériologie - CHU de Strasbourg - France
Strasbourg, France, 67091